Mary Vinson

Mary Vinson has a diverse work experience in the biotechnology and pharmaceutical industry. Mary is currently serving as the VP Cell Therapy Program Leader at bit.bio since September 2022. Prior to this, they worked at Autolus Ltd. from 2015 to 2022, holding multiple roles including VP Projects and Portfolio, Senior Director of Portfolio and Projects, Portfolio and Projects Director, and Project Director. Before Autolus Ltd., they worked at Heptares as a Development Program Leader from 2012 to 2015. From 2009 to 2012, they were the Preclinical Programme Director at Cantab Biopharmaceuticals Ltd (formerly Novacta). Earlier in their career, they served as the Group Head of Project Management at Proximagen from 2007 to 2009. Mary began their career at GlaxoSmithKline as an Investigator from 1997 to 2007.

Mary Vinson's education history begins in 1993 when they enrolled at the University of Oxford. Mary pursued a DPhil degree in the field of cell biology and immunology, completing their studies in 1997.